Propiedad y actividad de insiders de Akebia Therapeutics, Inc. (AKBA): operaciones de insiders, transacciones del Senado y la Cámara de EE. UU. y acciones en circulación. Sigue cómo operan la acción los directivos y los políticos.
Precio
| Precio | $0.92 |
| Capitalización | $246M |
| Bolsa | NASDAQ |
| País | US |
Operaciones Recientes de Insiders
| Fecha | Insider | Tipo | Acciones | Valor |
|---|---|---|---|---|
| 2026-08-06 | Butler John P. | M-Exempt | 350,000 | $220K |
| 2026-08-06 | Butler John P. | M-Exempt | 350,000 | $220K |
| 2026-06-29 | Ostrowski Erik | S-Sale | 56,019 | $62K |
| 2026-06-17 | Wolf Myles | A-Award | 35,700 | |
| 2026-06-17 | Wolf Myles | A-Award | 53,600 | $55K |
| 2026-06-17 | Smith Cynthia | A-Award | 35,700 | |
| 2026-06-17 | Smith Cynthia | A-Award | 53,600 | $55K |
| 2026-06-17 | ROGERS MICHAEL W | A-Award | 35,700 | |
| 2026-06-17 | ROGERS MICHAEL W | A-Award | 53,600 | $55K |
| 2026-06-17 | FRIESON RON | A-Award | 35,700 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $187.3M | $70.2M | $104.6M | $147.7M | $229.1M | $149.8M | $90.5M | $42.9M | $51.9M | $184.8M |
| Inversiones a Corto | $73.0M | $247.6M | $217.0M | $245000 | $40.0M | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $33.8M | $34.2M | $16.7M | $38.9M | $28.6M | $51.6M | $40.3M | $39.3M | $34.4M | $47.0M |
| Inventario | 0 | 0 | $114.2M | $116.3M | $61.0M | $36.6M | $21.6M | $15.7M | $16.2M | $15.6M |
| Activos Corrientes | $296.3M | $358.4M | $468.3M | $309.5M | $371.4M | $271.1M | $185.2M | $118.1M | $113.8M | $184.8M |
| Inmovilizado Material | $2.6M | $3.6M | $8.0M | $39.4M | $35.5M | $40.6M | $34.4M | $16.0M | $10.4M | 0 |
| Fondo de Comercio | 0 | 0 | $55.1M | $55.1M | $55.1M | $59.0M | $59.0M | $59.0M | $59.0M | $59.0M |
| Activos Intangibles | 0 | 0 | $328.2M | $291.2M | $144.2M | $108.1M | $72.1M | $36.0M | 0 | 0 |
| Activos Totales | $300.2M | $364.2M | $996.5M | $771.2M | $644.1M | $529.3M | $356.1M | $241.7M | $220.7M | $376.6M |
| Cuentas por Pagar | $2.0M | $7.0M | $42.8M | $39.2M | $41.3M | $33.6M | $18.0M | $14.6M | $15.2M | $21.2M |
| Deuda a Corto | 0 | 0 | $15.0M | $5.0M | $5.3M | $97.5M | $32.0M | $19.5M | $4.3M | $40.1M |
| Pasivos Corrientes | $114.3M | $144.3M | $265.7M | $208.1M | $187.1M | $261.1M | $129.5M | $99.9M | $80.9M | $162.9M |
| Deuda a Largo | 0 | 0 | 0 | $75.8M | $96.4M | $53.1M | $34.1M | $71.2M | $175.5M | $176.2M |
| Pasivos Totales | $232.1M | $244.9M | $360.6M | $376.4M | $396.5M | $455.3M | $350.8M | $272.3M | $269.9M | $344.0M |
| Reservas | -$297.1M | -$374.1M | -$514.4M | -$794.1M | -$1.18B | -$1.46B | -$1.56B | -$1.61B | -$1.68B | -$1.68B |
| Patrimonio Neto | $68.1M | $119.3M | $635.9M | $394.8M | $247.6M | $74.0M | $5.2M | -$30.6M | -$49.2M | $32.6M |
| Deuda Total | 0 | 0 | $15.0M | $108.3M | $126.3M | $189.1M | $99.8M | $104.2M | $188.7M | $216.3M |
| Deuda Neta | -$260.3M | -$317.8M | -$306.6M | -$39.6M | -$142.8M | $39.3M | $9.3M | $61.3M | $136.9M | $31.5M |
| Capital Circulante | $182.1M | $214.0M | $202.6M | $101.4M | $184.3M | $10.1M | $55.6M | $18.3M | $32.9M | $21.9M |
Salud financiera
| Deuda / Patrimonio | 2.16 |
| Ratio corriente | 1.43 |
| Piotroski F-Score | 6 |
| Altman Z-Score | -4.63 |
Rentabilidad
| Rentabilidad sobre capital | -93.74% |
| Rentabilidad sobre capital invertido | -7.08% |
| Rentabilidad sobre activos | -8.48% |
| Margen bruto | 79.48% |
| Margen operativo | -6.91% |
| Margen neto | -13.54% |
Empresas relacionadas: CMPX · CRVS · FDMT · GOSS · KALV · OLMA · PRTA
Explorar sector: Healthcare · Biotechnology
Más secciones de AKBA: Resumen · Financieros · Valoración · Estadísticas · Estimaciones · Técnico · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones